Is BridgeBio Pharma, Inc. (BBIO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 14.7% / 30% | 4.6% / 30% | 1.1% / 30% | 3.95% / 5% | ✓ HALAL |
| DJIM | 14.7% / 33% | 4.6% / 33% | 1.1% / 33% | 3.95% / 5% | ✓ HALAL |
| MSCI | 199.0% / 33% | 62.8% / 33% | 14.9% / 33% | 3.95% / 5% | ✗ NOT HALAL |
| S&P | 14.7% / 33% | 4.6% / 33% | 1.1% / 33% | 3.95% / 5% | ✓ HALAL |
| FTSE | 199.0% / 33% | 62.8% / 33% | 14.9% / 50% | 3.95% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 95.8% | |
| Operating Margin | -83.3% | |
| Net Margin | -144.4% | |
| Return on Assets (ROA) | -33.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$446M |
| Free Cash Flow | -$456M |
| Total Debt | $1.9B |
| Current Ratio | 2.8 |
| Total Assets | $936M |
Price & Trading
| Last Close | $72.58 |
| 50-Day MA | $71.86 |
| 200-Day MA | $60.73 |
| Avg Volume | 2.9M |
| Beta | 1.2 |
|
52-Week Range
$28.32
| |
About BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Purification Calculator
As a halal stock with 3.95% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BridgeBio Pharma, Inc. (BBIO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BridgeBio Pharma, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BridgeBio Pharma, Inc.'s debt ratio?
BridgeBio Pharma, Inc.'s debt ratio is 14.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 199.0%.
Does BridgeBio Pharma, Inc. require dividend purification?
Yes, BridgeBio Pharma, Inc. has an impermissible income ratio of 3.95%, which means 3.95% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are BridgeBio Pharma, Inc.'s key financial metrics?
BridgeBio Pharma, Inc. has a market capitalization of $13.5B, and revenue of $502M. The company maintains a gross margin of 95.8% and a net margin of -144.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.